Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 24INDUSTRY 18OTHER_GOV 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 13Cisplatin 12Carboplatin 12Drug Therapy 10Gemcitabine 8Gefitinib 8Docetaxel 8camrelizumab 5apatinib 5Radiotherapy 5Paclitaxel 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Endostatins 5tislelizumab 4pembrolizumab 4endostar protein 4Simvastatin 4Bevacizumab 4anlotinib 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Etoposide 3toripalimab 2surufatinib 2olaparib 2durvalumab 2atezolizumab 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × lorlatinib × Thoracic × Clear all
NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡